Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.IRD · Entity 5892 | Chief Scientific & Dev. Ofc. | April 23, 2026 | April 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date April 23, 2026 · Filed April 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 509,233 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Sale · Disposed 7,542 · Balance 509,233 F1: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. F2: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.18 to $5.21, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.
F2: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.18 to $5.21, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2026 Filed Apr 27, 2026 20:26 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 7,542 | $5.19 | $39,155.80 |
DisclosureSEC source: 0000905148-26-001863 · form4.xml · nonDerivative · entry 1 Jayagopal Ashwath · CIK 0002008983 · Chief Scientific & Dev. Ofc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,233 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. F2 · price: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.18 to $5.21, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:09 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 3,719 | $5.12 | $19,046.11 |
DisclosureSEC source: 0000905148-26-001380 · form4.xml · nonDerivative · entry 1 Jayagopal Ashwath · CIK 0002008983 · Chief Scientific & Dev. Ofc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,775 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. F2 · price: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.11 to $5.1301, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:14 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Tax withholdingCommon Stock | 5,313 | $3.39 | $18,011.07 |
DisclosureSEC source: 0000905148-26-000904 · form4.xml · nonDerivative · entry 1 Jayagopal Ashwath · CIK 0002008983 · Chief Scientific & Dev. Ofc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,494 F1 · kind: The Issuer withheld the shares reported on this line to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. Not an open market sale of securities. Read SEC document |
| January 22, 2026 Filed Jan 27, 2026 00:46 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000355 · form4.xml · nonDerivative · entry 1 Jayagopal Ashwath · CIK 0002008983 · Chief Scientific & Dev. Ofc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,807 F1 · shares: Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service. Read SEC document |
| March 13, 2025 Filed Mar 18, 2025 00:50 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 52,500 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000905148-25-000938 · form4.xml · derivative · entry 2 Jayagopal Ashwath · CIK 0002008983 · Chief Scientific & Dev. Ofc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2035-03-12 F2 · derivative.exercise_date: The option will vest with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly in 12 equal installments thereafter at the end of each quarter, subject to the Reporting Person's continuing service. Read SEC document |
| March 13, 2025 Filed Mar 18, 2025 00:50 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000938 · form4.xml · nonDerivative · entry 1 Jayagopal Ashwath · CIK 0002008983 · Chief Scientific & Dev. Ofc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,807 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of March 13, 2025, subject to the Reporting Person's continuing service. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:04 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Tax withholdingCommon Stock | 5,193 | $1.15 | $5,971.95 |
DisclosureSEC source: 0000905148-25-000712 · form4.xml · nonDerivative · entry 1 Jayagopal Ashwath · CIK 0002008983 · Chief Scientific & Dev. Ofc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,307 Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:07 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseCommon Stock | 3,500 | $1.77 | $6,177.50 |
DisclosureSEC source: 0000905148-24-001625 · form4.xml · nonDerivative · entry 1 Jayagopal Ashwath · CIK 0002008983 · Chief Scientific & Dev. Ofc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,500 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 23:35 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0000905148-24-000742 · form4.xml · derivative · entry 2 Jayagopal Ashwath · CIK 0002008983 · Chief Scientific & Dev. Ofc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2034-02-11 F2 · derivative.exercise_date: The option will vest with respect to 25% on February 12, 2025, with the remaining shares vesting quarterly in 12 equal installments thereafter, subject to the Reporting Person's continuing service. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 23:35 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000742 · form4.xml · nonDerivative · entry 1 Jayagopal Ashwath · CIK 0002008983 · Chief Scientific & Dev. Ofc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of February 12, 2024, subject to the Reporting Person's continuing service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.